吉利德科学Gilead Sciences (GILD) 2006年年度报告「NASDAQ」.pdf

1、GILEAD SCIENCES 2006 ANNUAL REPORT Gilead Financial HighlightsNotes:The non-GAAP net income for 2004 and 2005 excluded stock-based compensation expense relating to SFAS 123(R)as we began expensing stock-based compensation on January 1,2006.The non-GAAP net income for 2004 excluded a make-whole payme

2、nt related to the redemption of our$345.0 million 2%convertible senior debt and a gain related to our warrants in Eyetech Pharmaceuticals,Inc.(acquired by OSI Pharmaceuticals,Inc.),which completed its initial public offering in 2004.The non-GAAP net income for 2005 excluded a one-time tax provision

3、benefit related to a qualified dividend distribution made under the American Jobs Creation Act of 2004.The non-GAAP net income for 2006 excluded the impact of IPR&D charges of$2.39 billion associated with the acquisitions of Corus in August 2006 and Myogen in November 2006.040506($in millions)$3,500

4、$3,000$2,500$2,000$1,500$1,000$500$0TOTAL REVENUE040506($in millions)$1,500$1,000$500$0OPERATING CASH FLOWGAAP Net Income(Loss)Non-GAAP Net IncomeHIV FranchiseAmBisomeHepseraOther040506($in millions)$3,000$2,500$2,000$1,500$1,000$500$0PRODUCT REVENUE($in millions)$2,000$1,500$1,000$500$0$500$1,000$1

5、,500NET INCOME(LOSS)04050601 Letter to Stockholders06 HIV/AIDS12 Hepatitis B and C14 Additional Marketed Products16 Respiratory and Cardiopulmonary Therapies20 Gilead in the Community22 Our Vision24 Corporate Information and Financial HighlightsGILEAD SCIENCES 2006 ANNUAL REPORT IIeana (front cover)

6、,living with HIV GILEAD SCIENCES 2006 ANNUAL REPORT WHY WERE HEREGilead Sciences,Inc.333 Lakeside DriveFoster City,CA 94404Phone:(650)574-3000Fax:(650)578-92641-800-GILEAD-5(1-800-445-3235)HEADQUARTERSGILEAD SCIENCES 2006 ANNUAL REPORT GILEAD SCIENCES 2006 ANNUAL REPORT Gilead Financial HighlightsNo